Allstocks.com's Bulletin Board Post New Topic  
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Stock Picks Only » NFLD Now's the time.

 - UBBFriend: Email this page to someone!    
Author Topic: NFLD Now's the time.
noahltl
New Member


Rate Member
Icon 1 posted      Profile for noahltl     Send New Private Message       Edit/Delete Post 
If you don't know about this stock, it is Northfield Laboratories. Their newest product, Polyheme tm, is a blood substitute. Manufactured from old blood stores, this product has unlimited shelf life and doesn't need to be typed. Several hospitals and emergency vehicles are using this product around the country with complete success. FDA approval is scheduled for the fall. At the present time, price is at low since it took off in the spring. Now is the time to buy. This stock should be in the $100 range when approval comes out. DD will follow
Posts: 2 | From: Noblesville, IN | Registered: Oct 2004  |  IP: Logged | Report this post to a Moderator
noahltl
New Member


Rate Member
Icon 1 posted      Profile for noahltl     Send New Private Message       Edit/Delete Post 
olyHeme® is a solution of chemically modified hemoglobin derived from human blood. Hemoglobin is the oxygen-carrying component of the human red blood cell. Northfield purchases donated blood from The American Red Cross and Blood Centers of America for use as the starting material for PolyHeme. The company uses a proprietary process of separation, filtration and chemical modification to produce PolyHeme. Hemoglobin is first extracted from red blood cells and filtered to remove impurities. The purified hemoglobin is next chemically modified using a multi-step process to create a polymerized form of hemoglobin designed to avoid the undesirable effects historically associated with hemoglobin-based blood substitutes, including vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. The modified hemoglobin is then incorporated into a solution which can be administered as an alternative to transfused blood. One unit of PolyHeme contains 50 grams of modified hemoglobin, approximately the same amount of hemoglobin delivered by one unit of transfused blood.
Posts: 2 | From: Noblesville, IN | Registered: Oct 2004  |  IP: Logged | Report this post to a Moderator
noahltl
New Member


Rate Member
Icon 1 posted      Profile for noahltl     Send New Private Message       Edit/Delete Post 
NORTHFIELD LABORATORIES ANNOUNCES PATIENT ENROLLMENT IN PHASE III URBAN AMBULANCE TRIAL TO BEGIN

EVANSTON, IL – DECEMBER 22, 2003—Northfield Laboratories Inc. (NASDAQ: NFLD) announced today that it has received clearance to begin patient enrollment in its pivotal Phase III urban ambulance trial with PolyHeme?, the Company’s oxygen-carrying blood substitute.

“I am gratified to report that Northfield has received notification of the first full approval by an Institutional Review Board (IRB) to proceed with patient enrollment in this trial,” said Steven A. Gould, M.D., Chairman and Chief Executive Officer. “This is a key accomplishment for Northfield, attributable to the diligence and perseverance of the many individuals involved in the challenge of embarking on such a complex trial. We anticipate multiple other final IRB approvals in the near future.

“We have scheduled a site initiation visit prior to the end of this month and patient enrollment will begin immediately thereafter,” said Dr. Gould.

The PolyHeme® urban ambulance trial is a controlled study designed to evaluate the safety and efficacy of PolyHeme® in treating severely injured and bleeding patients when blood is not immediately available. Patients meeting the eligibility criteria will be randomly assigned to receive infusions of either PolyHeme® or the current standard treatment, a saline solution. Treatment will begin before arrival at the hospital, either at the scene of the injury or in the ambulance, and continue during a 12-hour post injury period in the hospital. The study will enroll 720 patients and will be conducted at approximately 20 Level I trauma centers across the United States.

In this trial it may not be possible to obtain informed consent from the patient or a legally authorized representative due to the urgency of the situation and the extent of the injuries. The study is therefore being conducted under a federal regulation that allows research to be conducted in certain emergent, life-threatening situations using an exception from the requirement for informed consent. Authorization to proceed with patient enrollment under this regulation signifies that the IRB has completed its oversight and evaluation of the public disclosure and community consultation process that is required, as well as its comprehensive review of the study protocol.

About Northfield Laboratories
Northfield Laboratories Inc. is the leader in developing an oxygen- carrying blood substitute, PolyHeme(r), for the treatment of urgent, large volume blood loss in trauma and surgical settings. PolyHeme(r) is a solution of chemically modified human hemoglobin which simultaneously restores lost blood volume and hemoglobin levels and can be rapidly and massively infused. PolyHeme(r) requires no cross matching. It is immediately available and compatible with all blood types. It has an extended shelf life of over 12 months.

For further information on Northfield Laboratories, visit the website
at http://www.northfieldlabs.com


Posts: 2 | From: Noblesville, IN | Registered: Oct 2004  |  IP: Logged | Report this post to a Moderator
noahltl
New Member


Rate Member
Icon 1 posted      Profile for noahltl     Send New Private Message       Edit/Delete Post 
Northfield Laboratories, Inc.
Nov-11-2002 NEW STORY
Northfield Laboratories Receives FDA Response on Proposed Ambulance Trail
Oct-16-2002
Northfield Laboratories Proposes First Ambulance Blood Substitute Trial
Oct-16-2002
Northfield Laboratories Reports First-Quarter Results
Oct-9-2002
Northfield Laboratories Sets Date and Time for First Quarterly Conference Call
Oct-8-2002
Leading Trauma Surgeon Declares 'The Future Is Now' for Blood Substitutes
Oct-4-2002
Northfield Laboratories Collaborates With U.S. Army on PolyHeme(TM) Treatment IND
Oct-3-2002
Northfield Announces Certification of Annual Meeting Results
Sep-30-2002
Northfield Updates Shareholders Regarding Final Annual Meeting Results
Sep-27-2002
PolyHeme Data Presented at the 62nd Annual Meeting of the American Association For the Surgery of Trauma
Sep-24-2002
Northfield Announces Delay In Finalizing Annual Meeting Results
Sep-17-2002
Northfield Announces Annual Meeting Voting Results
Sep-13-2002
Northfield Announces Preliminary Results Of Board Elections
Sep-12-2002
Northfield Encourages Shareholders To Participate In Annual Meeting
Sep-12-2002
Northfield Responds to False Accusations by C. Robert Coates
Sep-12-2002
Webcast Alert: Northfield Laboratories Inc. Announces 2002 Annual Meeting Of Stockholders Webcast Friday September 13, 2002 at 11:00 am EDT
Sep-4-2002
Northfield to Webcast Annual Meeting Live
Aug-30-2002
Northfield CEO Sends Letter to Shareholders
Aug-30-2002
Northfield Responds to Claims of Dissident Shareholder
Aug-29-2002
Northfield Builds Support for PolyHeme in Medical and Scientific Communities
Aug-22-2002
Northfield Questions Credibility Of Dissident Director Nominees
Aug-9-2002
Northfield Laboratories Urges Shareholders to Review Proxy Materials And Return Blue Proxy Cards Immediately
Aug-1-2002
Northfield Laboratories Urges Caution Regarding Dissident Shareholder
Jul-24-2002
Northfield Laboratories Announces Board and Management Changes
Jul-11-2002
Northfield Laboratories Receives Director Nominations
Jun-5-2002
Northfield Laboratories Trauma Data to Be Published by The Journal of The American College Of Surgeons
May-15-2002
Northfield Laboratories Comments on Stock Activity
May-9-2002
Northfield Laboratories Presents at Deutsche Banc Alex. Brown Healthcare Conference
May-7-2002
Northfield Laboratories To Present At Deutsche Banc Alex. Brown Healthcare Conference
Apr-15-2002
Northfield Laboratories Reports Fiscal 2002 Third Quarter Results
Jan-11-2002
Northfield Laboratories Reports Fiscal 2002 Second Quarter Results
Dec-21-2001
Northfield Laboratories to Schedule Meeting With FDA to Discuss Application
Nov-19-2001
Northfield Labs Receives FDA Comments on Application For Blood Substitute
Oct-16-2001
Northfield Laboratories Reports Fiscal 2002 First Quarter Results
Oct-11-2001
Northfield Labs Trauma Data Establish PolyHeme's Remarkable Life-Sustaining Capacity as Blood Substitute
Sep-4-2001
Northfield Discusses Strength of Data and FDA Application
Aug-28-2001
Northfield Laboratories Invites You to Listen to Its Annual Business Update On The Web
Aug-28-2001
Northfield Laboratories Submits Biologics License Application to FDA For Approval of Its Blood Substitute, PolyHeme(TM)
Aug-20-2001
Northfield Confirms Annual Meeting Date as August 31; Lawsuit to Postpone Meeting Dismissed
Aug-17-2001
Northfield Laboratories Sees No Merit in Suit to Postpone Annual Meeting
Aug-16-2001
Northfield Intends to Submit FDA Application Before Labor Day; Data Analysis For Application Complete
Aug-3-2001
Northfield Laboratories Reports Fiscal 2001 Results; Annual Meeting Set For Late August
May-11-2001
Northfield Laboratories Discussed Regulatory Statusa and Product Advantages At Deutsche Banc Alex. Brown Healthcare Conference
May-8-2001
Northfield Laboratories to Webcast Presentation at Deutsche Banc Alex Brown Healthcare Conference
Apr-17-2001
Northfield Laboratories Reports Fiscal 2001 Third Quarter Results
Jan-12-2001
Northfield Laboratories Reports Fiscal 2001 Second Quarter Results
Nov-7-2000
Northfield Laboratories Presents Business and Clinical Updates At Investor and Scientific Forums
Oct-18-2000
Northfield Laboratories Reports Fiscal 2001 First Quarter Results
Oct-12-2000
Northfield Laboratories' Management Enthusiastic About Future Prospects
Oct-9-2000
Northfield Laboratories 2000 Annual Meeting This Week; Business Update Accessible Online
Sep-26-2000
Northfield Labs and C. Robert Coates and Management Insights Reach Agreement
Aug-25-2000
Northfield Laboratories Reports Fiscal 2000 Results; To Host Annual Meeting Online
Jul-28-2000
Northfield Laboratories Sets Annual Meeting Date
Apr-18-2000
Northfield Laboratories Reports Fiscal 2000 Third Quarter Results
Jan-14-2000
Northfield Laboratories Reports Fiscal 2000 Second Quarter Results
Oct-20-1999
Northfield Laboratories Reports Results for First Quarter
Aug-30-1999
Northfield Laboratories Reports Fiscal 1999 Results
May-4-1999
Northfield Labs Reports Results of Blood Substitute Research; Tells HHS Committee Polyheme Improves Survival in Trauma
Apr-29-1999
Northfield Labs to Present Results to Health and Human Services Committee On Blood Safety and Availability
Apr-15-1999
Northfield Laboratories Reports Fiscal 1999 Third Quarter Results
Oct-19-1998
Northfield Laboratories Reports Results for First Quarter
Sep-2-1998
Northfield Laboratories Reports Fiscal 1998 and Fourth Quarter Results
Aug-12-1998
Northfield Asked to Expand Patient Numbers in Phase III Trials in Elective Surgery;
May-12-1998
Northfield Laboratories to Start European Trials of Blood Substitute With Pharmacia & Upjohn AB
May-8-1998
Northfield Laboratories Names David A. Savner Director
Jan-21-1998
Northfield Laboratories Reports Second Quarter Results; Phase III Trials of Blood Substitute Continue
Oct-16-1997
Northfield Reports Clinical Success to the American College of Surgeons
Oct-15-1997
Northfield Laboratories Reports Results For First Quarter
Sep-4-1997
Northfield Laboratories Initiates Phase III Trials of Blood Substitute; Reports Results for Fiscal Year
May-6-1997
Northfield Laboratories Enters Home Stretch For Blood Substitute Product
Apr-16-1997
Northfield Laboratories Reports Results For Third Quarter
Apr-2-1997
Northfield Laboratories Cleared For Phase III Blood Substitute Trials; First To Enter Phase III At Large Doses

Posts: 2 | From: Noblesville, IN | Registered: Oct 2004  |  IP: Logged | Report this post to a Moderator
casico
Member


Rate Member
Icon 1 posted      Profile for casico     Send New Private Message       Edit/Delete Post 
i know Several people from this company...
They are looking for jobs...take that for what it is worth

Posts: 88 | From: ft lauderdale ,fl usa | Registered: Apr 2004  |  IP: Logged | Report this post to a Moderator
mr.meoff
Member


Rate Member
Icon 1 posted      Profile for mr.meoff     Send New Private Message       Edit/Delete Post 
What is that suppose to mean? I have looked for a job before, when there was nothing wrong with the company. I was looking for advancement
Posts: 5 | From: Greeleyville, SC, USA | Registered: May 2004  |  IP: Logged | Report this post to a Moderator
noahltl
New Member


Rate Member
Icon 1 posted      Profile for noahltl     Send New Private Message       Edit/Delete Post 
NOrthfield was updated to NASDAQ yesterday. This company has nothing but big green in its future.
Posts: 2 | From: Noblesville, IN | Registered: Oct 2004  |  IP: Logged | Report this post to a Moderator
noahltl
New Member


Rate Member
Icon 1 posted      Profile for noahltl     Send New Private Message       Edit/Delete Post 
Still making a steady climb up. Now at $13.00. This stock was brought down by a recent issue at $12 while it was trading around 15 to raise funds for preparation for FDA approval. It normally trades around 15 but has seen 19 this spring. The low is artificial and it will continue to rise. When FDA approval comes out in fall the sky's the limit.
Posts: 2 | From: Noblesville, IN | Registered: Oct 2004  |  IP: Logged | Report this post to a Moderator
   

Post New Topic   Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share